TAT-Modified ω-Conotoxin MVIIA for Crossing the Blood-Brain Barrier
As the first in a new class of non-opioid drugs, ω-Conotoxin MVIIA was approved for the management of severe chronic pains in patients who are unresponsive to opioid therapy. Unfortunately, clinical application of MVIIA is severely limited due to its poor ability to penetrate the blood-brain ba...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI AG
2019-05-01
|
| Colección: | Marine Drugs |
| Materias: | |
| Acceso en línea: | https://www.mdpi.com/1660-3397/17/5/286 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|